These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37039113)

  • 1. Effect of formulation and route of administration on the distribution of 17-hydroxyprogesterone caproate in rats.
    Shaik IH; Chaphekar N; Vasudevan V; Alshabi A; Bastian JR; Zhao W; Caritis S; Venkataramanan R
    Xenobiotica; 2023 Mar; 53(3):193-200. PubMed ID: 37039113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Route of administration and formulation dependent pharmacokinetics of 17-hydroxyprogesterone caproate in rats.
    Shaik IH; Bastian JR; Zhao Y; Caritis SN; Venkataramanan R
    Xenobiotica; 2016; 46(2):169-74. PubMed ID: 26153441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaginal progesterone vs intramuscular 17α-hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth in singleton gestations: systematic review and meta-analysis of randomized controlled trials.
    Saccone G; Khalifeh A; Elimian A; Bahrami E; Chaman-Ara K; Bahrami MA; Berghella V
    Ultrasound Obstet Gynecol; 2017 Mar; 49(3):315-321. PubMed ID: 27546354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised trial to compare 200 mg micronised progesterone effervescent vaginal tablet daily with 250 mg intramuscular 17 alpha hydroxy progesterone caproate weekly for prevention of recurrent preterm birth.
    Shambhavi S; Bagga R; Bansal P; Kalra J; Kumar P
    J Obstet Gynaecol; 2018 Aug; 38(6):800-806. PubMed ID: 29557230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial.
    Boelig RC; Schoen CN; Frey H; Gimovsky AC; Springel E; Backley S; Berghella V
    Am J Obstet Gynecol; 2022 May; 226(5):722.e1-722.e12. PubMed ID: 35189093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate.
    Fukuda T; Kyozuka H; Murata T; Yasuda S; Yamaguchi A; Fujimori K
    J Obstet Gynaecol Res; 2021 Sep; 47(9):3119-3126. PubMed ID: 34219326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant 17-hydroxyprogesterone caproate in women withultrasound-indicated cerclage: a systematic review and meta-analysis.
    Lichter KE; Sheffield J; Graham EM; Eke AC
    J Matern Fetal Neonatal Med; 2020 Sep; 33(18):3177-3184. PubMed ID: 30626240
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant 17-hydroxyprogesterone caproate in women with history-indicated cerclage: A systematic review and meta-analysis.
    Eke AC; Sheffield J; Graham EM
    Acta Obstet Gynecol Scand; 2019 Feb; 98(2):139-153. PubMed ID: 30339274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Possible Mechanism of Action of 17α-Hydroxyprogesterone Caproate: Enhanced IL-10 Production.
    Megli CJ; Hauspurg A; Venkataramanan R; Caritis SN
    Am J Perinatol; 2023 Oct; 40(14):1585-1589. PubMed ID: 34784615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization, adherence, and outcomes of 17-alpha hydroxyprogesterone caproate for recurrent spontaneous preterm birth prevention.
    Zhang S; Rascati KL
    Curr Med Res Opin; 2021 Sep; 37(9):1667-1675. PubMed ID: 34030550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.
    Caritis SN; Simhan HN; Zhao Y; Rouse DJ; Peaceman AM; Sciscione A; Spong CY; Varner MW; Malone FD; Iams JD; Mercer BM; Thorp JM; Sorokin Y; Carpenter M; Lo J; Ramin SM; Harper M;
    Am J Obstet Gynecol; 2012 Nov; 207(5):396.e1-8. PubMed ID: 22959763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
    Blackwell SC; Gyamfi-Bannerman C; Biggio JR; Chauhan SP; Hughes BL; Louis JM; Manuck TA; Miller HS; Das AF; Saade GR; Nielsen P; Baker J; Yuzko OM; Reznichenko GI; Reznichenko NY; Pekarev O; Tatarova N; Gudeman J; Birch R; Jozwiakowski MJ; Duncan M; Williams L; Krop J
    Am J Perinatol; 2020 Jan; 37(2):127-136. PubMed ID: 31652479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation.
    Sharma S; Caritis S; Hankins G; Miodovnik M; Hebert MF; Mattison D; Venkataramanan R
    Br J Clin Pharmacol; 2016 Oct; 82(4):1084-93. PubMed ID: 27133963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of 17 alpha hydroxyprogesterone caproate in singleton pregnancy and its influence of maternal body size measures.
    Della Torre M; Enakpene C; Ravangard S; DiGiovanni L; Deyo K; Whelan A; Sutherland M; Fischer J
    Am J Obstet Gynecol MFM; 2019 Nov; 1(4):100051. PubMed ID: 33345841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent Preterm Birth Reduction by 17-Hydroxyprogesterone Caproate in Dichorionic/Diamniotic Twin Gestation.
    Megli C; Combs CA; Venkataramanan R; Lemon L; Caritis SN
    Am J Perinatol; 2022 Aug; 39(11):1183-1188. PubMed ID: 33321529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety.
    O'Brien JM; Lewis DF
    Am J Obstet Gynecol; 2016 Jan; 214(1):45-56. PubMed ID: 26558340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of treatment with 17 alpha-hydroxyprogesterone caproate on changes in cervical length over time.
    Durnwald CP; Lynch CD; Walker H; Iams JD
    Am J Obstet Gynecol; 2009 Oct; 201(4):410.e1-5. PubMed ID: 19716117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.
    Feghali M; Venkataramanan R; Caritis S
    Semin Perinatol; 2014 Dec; 38(8):516-22. PubMed ID: 25256193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review and meta-analysis of randomized controlled trials comparing 17-alpha-hydroxyprogesterone caproate versus placebo for the prevention of recurrent preterm birth.
    Fernandez-Macias R; Martinez-Portilla RJ; Cerrillos L; Figueras F; Palacio M
    Int J Gynaecol Obstet; 2019 Nov; 147(2):156-164. PubMed ID: 31402445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.